Table 1.
Clinical characteristics of study participants.
| CF | nonCF | |
|---|---|---|
| N | 10 | 12 |
| Percent Female | 20% | 75% |
| Age Mean (s.d.) | 29 (4.5) | 35 (11.9) |
| FEV1% predicted Mean (range) | 82 (27–133) | |
| BMI Mean (s.d.) | 25.9 (3.7) | |
| Pa positive | 7/10 | |
| Duration of Pa colonization in years Mean (s.d.) | 3.7 (1.9) | |
| Other bacterial colonization | ||
| Staphylococcus aureus | 4/10 | |
| Achromobacter xylosoxidans | 1/10 | |
| Moraxella catarrhalis | 1/10 | |
| CF-related diabetes | 4/10 | |
| Pancreatic insufficient | 10/10 | |
| Chronic azithromycin | 4/10 | |
| Inhaled aztreonam | 2/10 | |
| Inhaled tobramycin | 0/10 | |
| Nebulized DNAse | 4/10 | |
| Nebulized saline | 3/10 | |
| Annual outpatient exacerbation rate (past 3 years) Mean (s.d.) | 0.27 (0.33) | |
| Annual hospitalized exacerbation rate (past 3 years) Mean (s.d.) | 0.33 (0.33) |
MDM from a subset of subjects was used for each assay due to limitations on cell numbers from each isolation. All CF subjects were F508del homozygotes and on ETI at the time of blood draw.